Need Tally
for Clients?

Contact Us! Here

  Tally Auditor

License (Renewal)
  Tally Gold

License Renewal

  Tally Silver

License Renewal
  Tally Silver

New Licence
  Tally Gold

New Licence
 
Open DEMAT Account with in 24 Hrs and start investing now!
« Top Headlines »
Open DEMAT Account in 24 hrs
 8 reasons why old tax regime is still attractive for many taxpayers in this income tax bracket
 March 31 deadline is getting near. How to save income tax with tax loss harvesting?
 45-day MSME payment rule: Impact and details of Section 43B(h) explained
 Small savings schemes that offer tax benefits of up to Rs 1.5 lakh under section 80C
 RE-OPENING OF CORRECTION WINDOW FOR MAY 2024 CA EXAMINATIONS
 Powerful Upgrades, Tally 12+1 months renewal Plan and Connected Services for your growing Business - March 2024
 How innovative solutions can help fix the Sec 43B conundrum for MSMEs
 Income Tax dept asks many individuals to explain high value transactions of FY20-21 as Updated ITR deadline nears
 Release Notes for TallyPrime and TallyPrime Edit Log Release 4.1 | What s New!
 Deadline to file updated ITR FY20-21 ends on March 31: Details on additional tax
 4 tax-planning mistakes to avoid this season

Pharma sector mulls alternative tax incentive package
January, 09th 2007

The pharma industry on Tuesday will propose a package of tax incentives that the Union Finance Minister, Mr P. Chidambaram, could consider to encourage research and development (R&D) spend.

This package is an alternative for the Minister to consider if the industry's existing demand of extending the 150 per cent weighted tax deduction on R&D spend by 10 more years does not find favour with the Government.

Pharma industry captains are expected to meet Mr Chidambaram on Tuesday as part of the pre-budget consultations with the industry.

Alternative package

The alternative package comprises 100 per cent deduction on R&D revenue expenditure incurred for the business of the assessee. This should cover direct expenditure, sponsored research and contribution made to approved institutions.

As part of the package, the pharma industry is set to suggest an accelerated depreciation of 100 per cent on R&D capital expenditure including cost of building.

It also wants tax credit to be fixed at the rate of 20 per cent on total R&D revenue expenditure incurred during the year, with the unused credit allowed to be carried forward for 15 years.

Pharma and biotech industry are by far the highest spenders on R&D, together accounting for Rs 2,000 crore, say industry leaders. They claim that this figure was twice as much as what the auto industry spends and four times as much as the IT industry spends on R&D.

Sources said that industry will also seek tax exemptions under the Sections 10A and 10B of the Income-Tax Law to be extended to biotechnology, healthcare, R&D and clinical trial activities.

Home | About Us | Terms and Conditions | Contact Us
Copyright 2024 CAinINDIA All Right Reserved.
Designed and Developed by Ritz Consulting